蘇 柏嵐

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. ErbB Receptors 70%
3. Protein-Tyrosine Kinases 65%
4. Mutation 36%
5. Survival 32%
6. capmatinib 28%
7. Afatinib 26%
8. osimertinib 24%
9. Quarantine 22%
10. Adenocarcinoma of Lung 22%
11. Pandemics 22%
12. trametinib 21%
13. Erlotinib Hydrochloride 21%
14. Gefitinib 20%
15. Critical Illness 19%
16. Cohort Studies 19%
17. Drug Therapy 18%
18. Observational Studies 16%
19. Therapeutics 15%
20. Ventilation 12%
21. Positive-Pressure Respiration 12%
22. pembrolizumab 11%
23. Brain 11%
24. Adrenergic alpha-1 Receptor Antagonists 11%
25. Interactive Ventilatory Support 11%
26. Lung 11%
27. Retrospective Studies 11%
28. Rehabilitation 10%
29. Primary Effusion Lymphoma 10%
30. Ligands 10%
31. Crizotinib 10%
32. Pulmonary Aspergillosis 10%
33. Invasive Pulmonary Aspergillosis 10%
34. Lymphocytes 9%
35. Propensity Score 9%
36. Sleep Apnea Syndromes 9%
37. Pressure 9%
38. Human Herpesvirus 8 8%
39. Electric Impedance 8%
40. Coronavirus 8%
41. Human Influenza 8%
42. Adrenergic Antagonists 8%